Quick Take
Genfit S.A. (GNFT) intends to raise $130 million in a global IPO from the sale of ADSs representing underlying ordinary shares, per an amended registration statement.
The company is developing treatments for non-alcoholic steatohepatitis [NASH] conditions.
GNFT expects Phase 3 trial results for its primary candidate by the end of 2019 but is asking IPO investors to pay richly for the IPO.
Company & Technology
Loos, France-based Genfit was founded in 1999 to research treatments for non-alcoholic steatohepatitis, fibrosis, and auto-immune conditions.
Management is headed by Chairman, Co-founder and CEO